Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
23.40
-0.61 (-2.54%)
Jul 28, 2026, 12:42 PM EDT - Market open
Sutro Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -153.6 | -191.09 | -227.46 | -106.79 | -119.2 | -105.54 |
Depreciation & Amortization | 6.7 | 7.32 | 7.22 | 6.82 | 5.69 | 4.84 |
Stock-Based Compensation | 10.03 | 14.01 | 24.69 | 24.91 | 26.3 | 23.24 |
Other Adjustments | 41.76 | 42.92 | -4.88 | -2.17 | -13.65 | 13.39 |
Change in Receivables | 1.08 | 4.64 | 27.46 | -28.96 | 5.34 | -6.9 |
Changes in Accounts Payable | -3.13 | -2.47 | 0.71 | 4.81 | -1.23 | 2.71 |
Changes in Accrued Expenses | 0.2 | 5.29 | -9.14 | 26.84 | 8.29 | 8.46 |
Changes in Unearned Revenue | -66.91 | -69.73 | 7.85 | -32.6 | 93.65 | -15.21 |
Changes in Other Operating Activities | 10.57 | 11.87 | -17.98 | -4.48 | -1.65 | -6.69 |
Operating Cash Flow | -151.61 | -177.23 | -191.54 | -111.62 | 3.55 | -81.68 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.53 | -1.7 | -3.1 | -4.32 | -7.86 | -15.32 |
Purchases of Investments | -247.27 | -264.95 | -461.52 | -460.3 | -216.67 | -248.73 |
Proceeds from Sale of Investments | 263.81 | 311.66 | 683.13 | 460.69 | 189.5 | 166.73 |
Other Investing Activities | - | - | - | - | 0.01 | 0.01 |
Investing Cash Flow | -2.7 | 45.01 | 218.51 | -3.92 | -35.02 | -97.32 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | - | -4.08 | -12.5 | -9.38 | - |
Net Long-Term Debt Issued (Repaid) | - | - | -4.08 | -12.5 | -9.38 | - |
Issuance of Common Stock | 103.33 | 0.38 | 98.65 | 14.34 | 58.15 | 4.25 |
Repurchase of Common Stock | -0.31 | -0.33 | -0.51 | -0.49 | -0.46 | -0.99 |
Net Common Stock Issued (Repurchased) | 103.02 | 0.04 | 98.14 | 13.85 | 57.69 | 3.26 |
Other Financing Activities | - | - | - | 136.21 | - | - |
Financing Cash Flow | 103.05 | 0.04 | 94.05 | 137.55 | 48.31 | 3.26 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -32.55 | -132.17 | 121.02 | 22.01 | 16.84 | -175.74 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -152.14 | -178.93 | -194.64 | -115.93 | -4.31 | -97 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -152.74% | -174.59% | -313.72% | -75.41% | -6.36% | -156.76% |
Free Cash Flow Per Share | -15.70 | -21.06 | -25.16 | -19.27 | -0.85 | -21.03 |
Levered Free Cash Flow | -206.71 | -240.5 | -245.99 | -122.21 | -31.68 | -126.74 |
Unlevered Free Cash Flow | -172.52 | -207.7 | -255.4 | -110.53 | -34.81 | -119.73 |